Polo-Like Kinase 4’s Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy
Frontiers in Oncology, 2021 Polo-like kinases (Plks) are critical regulatory molecules during the cell cycle process. This family has five members: Plk1, 2, 3, 4, and 5. Plk4 has been identified as a master regulator of centriole replication, and its aberrant expression is closely ...
Lei Han, Zhang Xiaoyang
exaly +3 more sources
Migrasome-mediated clearance of excess PLK4 defines a targetable vulnerabilityResearch in context [PDF]
EBioMedicineSummary: Background: Centrosome amplification caused by Polo-like kinase 4 (PLK4) overexpression promotes tumour initiation, yet sustained PLK4 accumulation is detrimental to cancer cell viability.
Jihong Ma +12 more
doaj +2 more sources
Polo-like kinase 4: A molecular linchpin in cancer and its management [PDF]
iScienceSummary: Genomic instability and cell cycle dysregulation are considered hallmarks of cancer. Polo-like kinase 4 (PLK4), a member of the PLK family, is essential for faithful centriole duplication, which, when dysregulated, contributes to genomic ...
Durdana Muntaqua +3 more
doaj +2 more sources
Frontiers in Oncology, 2022 Tumor immune microenvironment plays an important role in tumorigenesis and metastasis. Polo-like kinases 4 (PLK4) is a crucial regulatory factor in the process of cell cycle, and its abnormal regulation often leads to a variety of diseases including ...
Zhang Xiaoyang +2 more
exaly +3 more sources
High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP [PDF]
World Journal of Surgical OncologyBackground Polo-like kinase 4 (PLK4) has been shown to be a tumor-promoting factor with multiple impacts on cancer growth, invasiveness, and treatment sensitivity.
Dehong Xu +4 more
doaj +2 more sources
A cis‐eQTL genetic variant in PLK4 confers high risk of hepatocellular carcinoma
Cancer Medicine, 2019 Purpose The overexpression and knockdown of PLK4 were both reported to generate aneuploidy. Thus, we aimed to investigate whether genetic variants in PLK4 contribute to the development of hepatocellular carcinoma (HCC).
Jing Han, Jiani Xu, Wenwen Yuan
exaly +2 more sources
PLK4 is a potential therapeutic target in nonmelanoma skin cancers: Evidence from molecular and in vivo studies. [PDF]
Photochem PhotobiolExposure to solar ultraviolet radiation is the main etiologic driver of nonmelanoma skin cancers (NMSCs), including basal cell (BCC) and cutaneous squamous cell carcinomas (cSCC), which are the most prevalent types of cancers in the US. In this study, we demonstrate that the serine/threonine kinase Polo‐like kinase 4 (PLK4) is overexpressed in NMSCs ...
Ndiaye MA +5 more
europepmc +2 more sources
Two-step phosphorylation of Ana2 by Plk4 is required for the sequential loading of Ana2 and Sas6 to initiate procentriole formation [PDF]
Open Biology, 2017 The conserved process of centriole duplication requires Plk4 kinase to recruit and promote interactions between Sas6 and Sas5/Ana2/STIL (respective nomenclature of worms/flies/humans).
Nikola S Dzhindzhev +2 more
exaly +2 more sources
Cholesterol Reprograms Oxysterol Metabolism via the LOX1/CH25H/CYP7B1 Signaling Axis to Drive Multidrug Resistance in Colorectal Cancer. [PDF]
Hum MutatChemotherapeutic resistance remains a major contributor to tumor recurrence and unfavorable clinical outcomes in colorectal cancer (CRC). Although cholesterol metabolic reprogramming has been implicated in tumorigenesis, metastasis, and drug resistance across multiple malignancies, its specific role in CRC chemoresistance requires systematic ...
Cheng H +6 more
europepmc +2 more sources
Frontiers in Genetics, 2022 Polo-like kinase 4 (PLK4), a key regulator of centriole biogenesis, is frequently overexpressed in cancer cells. However, roles and the mechanism of PLK4 in the leukemiagenesis of acute myeloid leukemia (AML) remain unclear.
, Qing-Yun Wu
exaly +3 more sources